These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 28097660)

  • 21. Myeloid-Derived Suppressor Cells in the Tumor Microenvironment: Current Knowledge and Future Perspectives.
    Ibáñez-Vea M; Zuazo M; Gato M; Arasanz H; Fernández-Hinojal G; Escors D; Kochan G
    Arch Immunol Ther Exp (Warsz); 2018 Apr; 66(2):113-123. PubMed ID: 29032490
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunotherapy Targeting Myeloid-Derived Suppressor Cells (MDSCs) in Tumor Microenvironment.
    Gao X; Sui H; Zhao S; Gao X; Su Y; Qu P
    Front Immunol; 2020; 11():585214. PubMed ID: 33613512
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Roles of the Exosomes Derived From Myeloid-Derived Suppressor Cells in Tumor Immunity and Cancer Progression.
    Chen Z; Yuan R; Hu S; Yuan W; Sun Z
    Front Immunol; 2022; 13():817942. PubMed ID: 35154134
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chemokines and their receptors promoting the recruitment of myeloid-derived suppressor cells into the tumor.
    Li BH; Garstka MA; Li ZF
    Mol Immunol; 2020 Jan; 117():201-215. PubMed ID: 31835202
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Suppression of T cells by myeloid-derived suppressor cells in cancer.
    Chen J; Ye Y; Liu P; Yu W; Wei F; Li H; Yu J
    Hum Immunol; 2017 Feb; 78(2):113-119. PubMed ID: 27939507
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immature myeloid cells in the tumor microenvironment: Implications for immunotherapy.
    Kamran N; Chandran M; Lowenstein PR; Castro MG
    Clin Immunol; 2018 Apr; 189():34-42. PubMed ID: 27777083
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunosuppressive cells and tumour microenvironment: focus on mesenchymal stem cells and myeloid derived suppressor cells.
    Bianchi G; Borgonovo G; Pistoia V; Raffaghello L
    Histol Histopathol; 2011 Jul; 26(7):941-51. PubMed ID: 21630223
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic prospects of targeting myeloid-derived suppressor cells and immune checkpoints in cancer.
    Toor SM; Elkord E
    Immunol Cell Biol; 2018 Oct; 96(9):888-897. PubMed ID: 29635843
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Myeloid-Derived Suppressor Cells: Immune-Suppressive Cells That Impair Antitumor Immunity and Are Sculpted by Their Environment.
    Ostrand-Rosenberg S; Fenselau C
    J Immunol; 2018 Jan; 200(2):422-431. PubMed ID: 29311384
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Suppressive role of myeloid-derived suppressor cells (MDSCs) in the microenvironment of breast cancer and targeted immunotherapies.
    Shou D; Wen L; Song Z; Yin J; Sun Q; Gong W
    Oncotarget; 2016 Sep; 7(39):64505-64511. PubMed ID: 27542274
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Myeloid Cell Modulation by Tumor-Derived Extracellular Vesicles.
    Arkhypov I; Lasser S; Petrova V; Weber R; Groth C; Utikal J; Altevogt P; Umansky V
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32878277
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Plasticity of myeloid-derived suppressor cells in cancer.
    Tcyganov E; Mastio J; Chen E; Gabrilovich DI
    Curr Opin Immunol; 2018 Apr; 51():76-82. PubMed ID: 29547768
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Periostin promotes immunosuppressive premetastatic niche formation to facilitate breast tumour metastasis.
    Wang Z; Xiong S; Mao Y; Chen M; Ma X; Zhou X; Ma Z; Liu F; Huang Z; Luo Q; Ouyang G
    J Pathol; 2016 Aug; 239(4):484-95. PubMed ID: 27193093
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mathematical modeling of tumor-induced immunosuppression by myeloid-derived suppressor cells: Implications for therapeutic targeting strategies.
    Shariatpanahi SP; Shariatpanahi SP; Madjidzadeh K; Hassan M; Abedi-Valugerdi M
    J Theor Biol; 2018 Apr; 442():1-10. PubMed ID: 29337259
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Emerging Role of Myeloid-Derived Suppressor Cells in the Glioma Immune Suppressive Microenvironment.
    Mi Y; Guo N; Luan J; Cheng J; Hu Z; Jiang P; Jin W; Gao X
    Front Immunol; 2020; 11():737. PubMed ID: 32391020
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metabolic Regulation of Myeloid-Derived Suppressor Cell Function in Cancer.
    Wang Y; Jia A; Bi Y; Wang Y; Liu G
    Cells; 2020 Apr; 9(4):. PubMed ID: 32325683
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of myeloid-derived suppressor cells in hematologic malignancies.
    Gunes EG; Rosen ST; Querfeld C
    Curr Opin Oncol; 2020 Sep; 32(5):518-526. PubMed ID: 32675593
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Myeloid-Derived Suppressor Cells.
    Gabrilovich DI
    Cancer Immunol Res; 2017 Jan; 5(1):3-8. PubMed ID: 28052991
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hepatic carcinoma-associated fibroblasts enhance immune suppression by facilitating the generation of myeloid-derived suppressor cells.
    Deng Y; Cheng J; Fu B; Liu W; Chen G; Zhang Q; Yang Y
    Oncogene; 2017 Feb; 36(8):1090-1101. PubMed ID: 27593937
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Myeloid-Derived Suppressor Cells: Ductile Targets in Disease.
    Consonni FM; Porta C; Marino A; Pandolfo C; Mola S; Bleve A; Sica A
    Front Immunol; 2019; 10():949. PubMed ID: 31130949
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.